Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;93(11):6292-6300.
doi: 10.1002/jmv.26861. Epub 2021 Feb 19.

Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV-IG prophylaxis: A monocentric retrospective analysis

Andrea Gilioli  1 , Andrea Messerotti  1 , Paola Bresciani  1 , Angela Cuoghi  1 , Valeria Pioli  1 , Corrado Colasante  1 , Francesca Bettelli  1 , Davide Giusti  1 , Fabio Forghieri  1 , Leonardo Potenza  1 , Francesca Donatelli  1 , Rachele Giubbolini  1 , Laura Galassi  1 , Roberto Marasca  1 , Federico Banchelli  2 , Roberto D'Amico  2 , Monica Pecorari  3 , William Gennari  3 , Tommaso Trenti  3 , Patrizia Comoli  4 , Mario Luppi  1 , Franco Narni  1
Affiliations

Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV-IG prophylaxis: A monocentric retrospective analysis

Andrea Gilioli et al. J Med Virol. 2021 Nov.

Abstract

Human cytomegalovirus (CMV) represents the most common viral infection after hematopoietic stem cell transplant (HSCT), mainly occurring as reactivation from latency in seropositive patients, with a different prevalence based on the extent and timing of seroconversion in a specific population. Here, we retrospectively analyzed a cohort of patients who underwent HSCT at our Institution between 2013 and 2018, all of whom were prophylactically treated with CMV-IG (Megalotect Biotest®), to define the incidence and clinical outcomes of CMV reactivation and clinically significant infection. CMV infection occurred in 69% of our patient series, mainly resulting from reactivation, and CMV clinically significant infection (CS-CMVi) occurred in 48% of prophylactically treated patients. CMV infection and CS-CMVi impacted neither on relapse incidence nor on overall survival nor on relapse-free survival. Moreover, a very low incidence of CMV end-organ disease was documented. CMV-IG used alone as prophylactic therapy after HSCT does not effectively prevent CMV reactivation.

Keywords: CMV; CMV prophylaxis; CMV-specific immunoglobulins; hematopoietic stem cell transplantation.

PubMed Disclaimer

References

REFERENCES

    1. Griffiths P , Baraniak I , Reeves M . The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288-297.
    1. de la Camara R . CMV in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016;8(1):e2016031.
    1. Locatelli F , Bertaina A , Bertaina V , Merli P . Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection. Expert Rev Hematol. 2016;9(11):1093-1105.
    1. Maffini E , Giaccone L , Festuccia M , Brunello L , Busca A , Bruno B . Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. 2016;9(6):585-596.
    1. Marty FM , Ljungman P , Chemaly RF , et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433-2444.

Publication types

MeSH terms